Works about PANITUMUMAB
Results: 89
Sotorasib Combo Bests Chemo Leading to Approval in KRAS G12C+ CRC.
- Published in:
- Oncology (08909091), 2025, v. 39, n. 2, p. 85
- By:
- Publication type:
- Article
Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 663, doi. 10.3390/cancers17040663
- By:
- Publication type:
- Article
A marginalized two‐part joint model for a longitudinal biomarker and a terminal event with application to advanced head and neck cancers.
- Published in:
- Pharmaceutical Statistics, 2024, v. 23, n. 1, p. 60, doi. 10.1002/pst.2338
- By:
- Publication type:
- Article
An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 23, p. 7108, doi. 10.3390/jcm11237108
- By:
- Publication type:
- Article
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1398419
- By:
- Publication type:
- Article
Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2020, v. 34, n. 12, p. 2789, doi. 10.1111/jdv.16465
- By:
- Publication type:
- Article
Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis.
- Published in:
- World Journal of Surgical Oncology, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12957-023-03256-7
- By:
- Publication type:
- Article
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 319, doi. 10.1007/s00280-023-04619-3
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2024
- Publication type:
- Correction Notice
Practical Notes on the Current ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer in Resource-Constrained Environments of Low- to Middle-Income Countries.
- Published in:
- 2023
- By:
- Publication type:
- Letter
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases--a phase II study.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1231600
- By:
- Publication type:
- Article
Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer .
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1138357
- By:
- Publication type:
- Article
Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1147497
- Publication type:
- Article
Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1112224
- By:
- Publication type:
- Article
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 01, doi. 10.3389/fonc.2023.1084681
- By:
- Publication type:
- Article
Publication trends and hotspots of drug resistance in colorectal cancer during 2002-2021: A bibliometric and visualized analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.947658
- By:
- Publication type:
- Article
A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
- Published in:
- BMC Medical Research Methodology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12874-024-02140-6
- By:
- Publication type:
- Article
Case report: a rare case of colorectal cancer diagnosed in a young pregnant woman – management and evolution.
- Published in:
- Oncolog-Hematolog, 2024, v. 69, n. 4, p. 28
- By:
- Publication type:
- Article
Drug-induced thrombocytopenia in a patient with colorectal cancer: A case report.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-08012-7
- By:
- Publication type:
- Article
Clinical outcomes of intermittent panitumumab based-therapy for previously treated older patient with metastatic colorectal cancer: a case report and review of literature.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1369952
- By:
- Publication type:
- Article
Editorial: Optimizing the first-line treatment for metastatic colorectal cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1366383
- By:
- Publication type:
- Article
PRIDE syndrome associated with panitumumab treatment - case report and literature review.
- Published in:
- Dermatology Review / Przeglad Dermatologiczny, 2023, v. 110, n. 1, p. 65, doi. 10.5114/dr.2023.127665
- By:
- Publication type:
- Article
Aphthous-Like Stomatitis in a Patient Receiving Panitumumab.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 6849, doi. 10.1007/s00432-023-04628-y
- By:
- Publication type:
- Article
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 10, p. 2681, doi. 10.1007/s00432-020-03257-z
- By:
- Publication type:
- Article
Exploring the Potential of Epiregulin and Amphiregulin as Prognostic, Predictive, and Therapeutic Targets in Colorectal Cancer.
- Published in:
- Onco, 2024, v. 4, n. 4, p. 257, doi. 10.3390/onco4040019
- By:
- Publication type:
- Article
A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
- Published in:
- Immunopharmacology & Immunotoxicology, 2023, v. 45, n. 1, p. 1, doi. 10.1080/08923973.2022.2112222
- By:
- Publication type:
- Article
Curative resection after percutaneous drainage followed by preoperative panitumumab monotherapy for locally advanced sigmoid colon cancer with intra-abdominal abscess: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Multidisciplinary management of locally recurrent rectal cancer with carbon ion radiotherapy followed by prophylactic removal of the irradiated bowel: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Evaluation of physicochemical and functional similarity of a new CHO derived anti-EGFR antibody P-mAb to its reference medicinal product.
- Published in:
- Artificial Cells, Nanomedicine & Biotechnology, 2022, v. 50, n. 1, p. 17, doi. 10.1080/21691401.2022.2028284
- By:
- Publication type:
- Article
The potential effect of Schisandrin‐B combination with panitumumab in wild‐type and mutant colorectal cancer cell lines: Role of apoptosis and autophagy.
- Published in:
- Journal of Biochemical & Molecular Toxicology, 2023, v. 37, n. 5, p. 1, doi. 10.1002/jbt.23324
- By:
- Publication type:
- Article
Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 11, p. 6731, doi. 10.1007/s00520-021-06134-8
- By:
- Publication type:
- Article
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 7, p. 3971, doi. 10.1007/s00520-020-05972-2
- By:
- Publication type:
- Article
Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.
- Published in:
- International Journal of Colorectal Disease, 2021, v. 36, n. 12, p. 2621, doi. 10.1007/s00384-021-04002-9
- By:
- Publication type:
- Article
A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.
- Published in:
- International Journal of Colorectal Disease, 2020, v. 35, n. 12, p. 2197, doi. 10.1007/s00384-020-03693-w
- By:
- Publication type:
- Article
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 4, p. e245635, doi. 10.1001/jamanetworkopen.2024.5635
- By:
- Publication type:
- Article
FDA Approves Sotorasib With Panitumumab for KRAS G12C-Variant Colorectal Cancer.
- Published in:
- ONS Voice, 2025, p. 2
- Publication type:
- Article
Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.1027890
- By:
- Publication type:
- Article
The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 01, doi. 10.3389/fphar.2022.1015510
- By:
- Publication type:
- Article
Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 11, p. 2620, doi. 10.3390/pharmaceutics15112620
- By:
- Publication type:
- Article
Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 480, doi. 10.3390/ph17040480
- By:
- Publication type:
- Article
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer.
- Published in:
- Case Reports in Oncology, 2021, v. 14, n. 1, p. 85, doi. 10.1159/000512821
- By:
- Publication type:
- Article
Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 3, p. 383, doi. 10.1007/s00280-020-04126-9
- By:
- Publication type:
- Article
Panitumumab w leczeniu chorych na raka jelita grubego.
- Published in:
- Gastroenterologia Kliniczna, 2022, v. 14, n. 4, p. 139
- By:
- Publication type:
- Article
Cancer therapy related cardiac dysfunction as a result of Panitumumab.
- Published in:
- Cardio-Oncology, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40959-024-00223-3
- By:
- Publication type:
- Article
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
- Published in:
- Oncologist, 2024, v. 29, n. 5, p. 431, doi. 10.1093/oncolo/oyad320
- By:
- Publication type:
- Article
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. e1209, doi. 10.1093/oncolo/oyad210
- By:
- Publication type:
- Article